NO20022246L - Behandling av subnormal benmineraltetthet - Google Patents

Behandling av subnormal benmineraltetthet

Info

Publication number
NO20022246L
NO20022246L NO20022246A NO20022246A NO20022246L NO 20022246 L NO20022246 L NO 20022246L NO 20022246 A NO20022246 A NO 20022246A NO 20022246 A NO20022246 A NO 20022246A NO 20022246 L NO20022246 L NO 20022246L
Authority
NO
Norway
Prior art keywords
treatment
bone mineral
mineral density
individual
agent
Prior art date
Application number
NO20022246A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022246D0 (no
Inventor
Kenneth E Schwartz
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of NO20022246D0 publication Critical patent/NO20022246D0/no
Publication of NO20022246L publication Critical patent/NO20022246L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20022246A 1999-11-12 2002-05-10 Behandling av subnormal benmineraltetthet NO20022246L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16508999P 1999-11-12 1999-11-12
US09/710,729 US6605591B1 (en) 1999-11-12 2000-11-10 Treatment of subnormal bone mineral density
PCT/US2000/030131 WO2001035975A2 (en) 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density

Publications (2)

Publication Number Publication Date
NO20022246D0 NO20022246D0 (no) 2002-05-10
NO20022246L true NO20022246L (no) 2002-07-03

Family

ID=26861107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022246A NO20022246L (no) 1999-11-12 2002-05-10 Behandling av subnormal benmineraltetthet

Country Status (16)

Country Link
US (3) US6605591B1 (de)
EP (1) EP1231983B1 (de)
JP (1) JP2003514026A (de)
KR (1) KR20020063183A (de)
CN (1) CN1411386A (de)
AT (1) ATE326265T1 (de)
AU (1) AU784160B2 (de)
BR (1) BR0015534A (de)
CA (1) CA2390431A1 (de)
DE (1) DE60028074D1 (de)
IL (1) IL149532A0 (de)
MX (1) MXPA02004776A (de)
NO (1) NO20022246L (de)
NZ (1) NZ518791A (de)
RU (1) RU2002115815A (de)
WO (1) WO2001035975A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US8639009B2 (en) * 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
ATE440536T1 (de) 2001-05-25 2009-09-15 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
JP2007524438A (ja) 2003-03-25 2007-08-30 イメージング セラピューティクス，インコーポレーテッド 放射線画像処理技術における補償の方法
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
WO2006034018A2 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
EP2061376A2 (de) * 2006-09-15 2009-05-27 Imaging Therapeutics, Inc. Verfahren und system zur bereitstellung einer bruch/nichtbruch-klassifizierung
EP2460515B1 (de) * 2007-08-09 2017-03-08 Novartis AG Orale Calcitonin-Zusammensetzungen und ihre Anwendungen
US8999962B2 (en) * 2008-06-03 2015-04-07 John Ray Biffin Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
EP0949928A4 (de) 1996-11-25 2000-09-13 Merck & Co Inc Zusammen verabreichte androgene und diphosphonverbindungen zur behandlung von krankheiten
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
RU2220727C2 (ru) 1999-03-18 2004-01-10 Дженелабс Текнолоджис, Инк. Композиция, содержащая дегидроэпиандростерон, и способы ее изготовления и применения
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density

Also Published As

Publication number Publication date
IL149532A0 (en) 2002-11-10
US6854468B2 (en) 2005-02-15
US7612034B2 (en) 2009-11-03
NO20022246D0 (no) 2002-05-10
KR20020063183A (ko) 2002-08-01
CA2390431A1 (en) 2001-05-25
AU1580201A (en) 2001-05-30
BR0015534A (pt) 2002-07-02
CN1411386A (zh) 2003-04-16
US6605591B1 (en) 2003-08-12
AU784160B2 (en) 2006-02-16
JP2003514026A (ja) 2003-04-15
WO2001035975A3 (en) 2001-12-27
US20050113301A1 (en) 2005-05-26
RU2002115815A (ru) 2004-02-27
DE60028074D1 (de) 2006-06-22
US20030158159A1 (en) 2003-08-21
ATE326265T1 (de) 2006-06-15
MXPA02004776A (es) 2003-01-28
NZ518791A (en) 2004-03-26
EP1231983A2 (de) 2002-08-21
EP1231983B1 (de) 2006-05-17
WO2001035975A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20022246L (no) Behandling av subnormal benmineraltetthet
DK0880350T3 (da) Behandling af dissemineret sklerose
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
BG105534A (en) 5ht1 means and method for the treatment of migraine
AU4098997A (en) Ammonium siloxane emulsions and their use as fiber treatment agents
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
WO2001010375A3 (en) Inhibition of action potentials
BR9708362A (pt) Utilização de uma quantidade eficaz de um extrato e processo de tratamento cosmético
NO995246L (no) Fremgangsmåte for fjerning av sjenerende hårvekst
BR9808606A (pt) Materiais e métodos para tratamento de doenças com ribozimas
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
NZ292940A (en) Use of an aromatase inhibitor and/or an androgen receptor anatonist as a cosmetic agent to reduce hair loss
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AU4946699A (en) Method of treating meniere's disease and corresponding apparatus
GB2331301B (en) Galanin
ZA981781B (en) The use of levobupivacaine in treating migraine
WO2000066098A3 (en) Vitamin d derivatives for the treatment of systemic lupus erythematosus
DE69530205D1 (de) Heterocyclisch kondensierte morphinoid-derivate
AU2003248816A8 (en) Composition for lessening malodors during hair treatment and hair removal and method of use
FI951024A0 (fi) Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät
PL349514A1 (en) Agents and method for treating keratinous fibres
NO984160D0 (no) Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt
BA98363A (bs) Postupak i uredaj za tretiranje koze i tome slicno
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application